<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02663102</url>
  </required_header>
  <id_info>
    <org_study_id>204687</org_study_id>
    <nct_id>NCT02663102</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.</brief_title>
  <official_title>Assessment of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information in Korea.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is collect safety information on the use of Fluarix Tetra according
      to the approved PI, over a period of 6 years from children (over 3 years of age) and adults
      in Korea.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adults and previously vaccinated children aged ≥36 months, a single dose of Fluarix Tetra
      will be administered. To previously unvaccinated children aged 36 months to &lt;9 years, two
      doses will be administered with a second dose at least 4 weeks apart from the first one as
      per the local PI in Korea.

      Fluarix Tetra may be administered to pregnant women/lactating women as per PI, if there is a
      clear need. Pregnancy outcome (whether full-term or premature, information on the status of
      the mother and child) in vaccinated pregnant subjects will be followed-up at 6-8 weeks after
      delivery, if possible.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2016</start_date>
  <completion_date type="Anticipated">June 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of expected and unexpected adverse events (AEs)</measure>
    <time_frame>During the 21 days (Day 0 to Day 20) follow-up period after vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events (SAEs)</measure>
    <time_frame>From the date of vaccination in the drug use investigation up to 21 days (Day 0 to Day 20) after vaccination of the subject in the drug use investigation</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Fluarix Tetra Group</arm_group_label>
    <description>Subjects aged 3 years and above who will receive Fluarix Tetra as per locally approved PI (which is not part of the drug use investigation).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data collection</intervention_name>
    <description>Safety monitoring and evaluation: ‒ Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. ‒ Recording of SAEs throughout the study period for each subject.</description>
    <arm_group_label>Fluarix Tetra Group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy subjects aged 3 years and above who were vaccinated with Fluarix Tetra or eligible
        to receive Fluarix Tetra in Korea according to the locally approved PI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects who were vaccinated with Fluarix Tetra or eligible to receive
             Fluarix Tetra according to the locally approved PI.

          -  Signed informed consent as Informed Consent Form (ICF)/Informed Assent Form (IAF)
             obtained from the subject/subject's parent(s)/Legally acceptable Representative(s)
             [LAR(s)].

        Exclusion Criteria:

          -  Those who are not eligible for vaccination with Fluarix Tetra according to the local
             PI.

               -  Hypersensitivity reaction to Fluarix Tetra.

               -  History of hypersensitivity reaction to Influenza vaccine.

               -  History of Guillain-Barre syndrome or other nervous system abnormalities to
                  Influenza vaccine within 6 weeks post-vaccination.

          -  Those who are not eligible for vaccination with Fluarix Tetra according to the medical
             judgement of physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>36 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Center</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>January 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2016</study_first_posted>
  <last_update_submitted>September 19, 2017</last_update_submitted>
  <last_update_submitted_qc>September 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Post-marketing</keyword>
  <keyword>Korea</keyword>
  <keyword>Drug utilization study</keyword>
  <keyword>Fluarix Tetra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

